Experimental pancreatic cancer vaccine elicits durable immune responses in high-risk parti
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low five-year survival rate. Approximately 10% of cases are associated with hereditary predisposition caused by pathogenic mutations in specific cancer suscept
